Tuesday, September 5, 2017
Sosei Group subsidiary Heptares Therapeutics has entered into a drug discovery and licensing agreement with Daiichi Sankyo focused on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain.
Sosei Group‘s wholly-owned subsidiary Heptares Therapeutics has entered into a definitive agreement with Allergan Pharmaceuticals International, a wholly owned subsidiary of Allergan, a global pharmaceutical company, under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.
Heptares Therapeutics, a subsidiary of the Sosei Group, has entered into a strategic drug discovery collaboration with Pfizer to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.
Teva Pharmaceutical Industries and Heptares Therapeutics, a wholly owned subsidiary of Sosei Group, have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine headaches.
Novartis and Sosei Group, an international biopharmaceutical company based in Japan, released results from the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) phase III study, SPARK, which met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler).
International biopharmaceutical and drug development company Sosei reports that NVA237, a long-acting muscarinic antagonist (LAMA) being investigated as a once daily treatment for chronic obstructive pulmonary disease (COPD), achieved its primary end point in a phase III study. The drug is licensed to Novartis; the company confirmed results from the first phase III clinical trial with once-daily NVA237 (glycopyrronium bromide) show that it significantly improved lung function while demonstrating a good safety profile in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).